Articles Related to HSCT
Novel Antibiotics for Bloodstream Infections in HSCT
Bloodstream infections (BSI) are one of severe infectious complications faced by hematopoietic stem cell transplantation (HSCT) patients. BSI increases significantly the morbidity and mortality of HSCT patients. Gram-positive bacteria occurred more frequency than gram-negative bacteria over past decades, but rates of gram-negative bloodstream infections have recently increased again. Antibacterial prophylaxis could be justified in HSCT, infections caused by resistant pathogens increased mortality. New antibiotics such as omadacycline, meropenem/vaborbactam, eravacycline, ceftobiprole, tedizolid, dalbavancin, cefiderocol hold promise for the treatment of highly resistant pathogens.
Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis
We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
Editorial Board Members Related to HSCT
Eva Mischak-Weissinger
Professor
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Germany
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Germany